Tareeva I E
Vestn Ross Akad Med Nauk. 1995(5):52-6.
The paper provides evidence and results of using new therapeutical treatment of glomerulonephritis, such as pulse-therapy with cyclophosphane, therapy with angiotension-converting enzyme (ACE) inhibitors or that with antihyperlipidemic agents. Based on much experience with pulse-therapy with cyclophosphane (over 100 patients with chronic glomerulonephritis (CGN) and lupus nephritis), it is concluded that this method is highly effective. Treating 57 patients with ACE inhibitors has shown that in CGN these drugs should be used only when taking into account their antihypertensive effect and capacity of lowering intraglomerular hypertension, as evidenced by the renal functional reserve, and diminishing proteinuria. The long-term (7-12 month) antihyperlipidemic therapy (diet and lovastatin) in 20 patients with CGN accompanied by the nephrotic syndrome caused a significant reduction in the concentration of serum cholesterol and proteinuria, a significant increase in serum albumin levels; remission of the nephrotic syndrome occurred in 9 patients; but better effects were observed in non-inflammatory nephropathies, such as membranous nephropathy, focal segmental glomerulosclerosis, and nephrosclerosis.
本文提供了使用肾小球肾炎新治疗方法的证据和结果，如环磷酰胺冲击疗法、血管紧张素转换酶（ACE）抑制剂治疗或抗高脂血症药物治疗。基于环磷酰胺冲击疗法的丰富经验（超过100例慢性肾小球肾炎（CGN）和狼疮性肾炎患者），得出该方法非常有效的结论。对57例患者使用ACE抑制剂的治疗表明，在CGN中，仅当考虑到其降压作用以及降低肾小球内高血压的能力（如肾功能储备所证明）和减少蛋白尿时，才应使用这些药物。对20例伴有肾病综合征的CGN患者进行的长期（7 - 12个月）抗高脂血症治疗（饮食和洛伐他汀）导致血清胆固醇浓度和蛋白尿显著降低，血清白蛋白水平显著升高；9例患者肾病综合征缓解；但在非炎症性肾病，如膜性肾病、局灶节段性肾小球硬化和肾硬化中观察到更好的效果。
